Andere talen Kancera AB

Aandelen

KAN

SE0015658570

Vertraagde tijd Nasdaq Stockholm Andere beurzen 11:59:15 07-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,398 ^SEK	-3,59%		-4,90%	-69,24%

03/05	Kancera AB (publ) meldt positieve resultaten van de klinische fase I studie met KAND145 bij gezonde proefpersonen	CI
23/02	Kancera AB (publ) rapporteert resultaten voor het gehele jaar eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Kancera meets the primary objectives of the KAND145 clinical phase I study	03/05
Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	03/05
Kancera announces the outcome of the company's rights issue	20/03
Kancera publishes prospectus in connection with the company’s rights issue	01/03
Kancera resolves on a rights issue of approximately SEK 121.9 million	23/02
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851	23/02
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study	23/02
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Kancera AB Signs A License Agreement with the University of Newcastle	23/02
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23/02
Kancera presents the statistical analysis of top line data from the FRACTAL study	06/02
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study	06/02
Kancera reports positive top line results from the FRACTAL study	20/12
Kancera AB Reports Positive Top Line Results from the FRACTAL Study	20/12
Kancera provides operational update in connection with release of financial interim report for third quarter 2023	17/11
Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851	17/11
Kancera AB Provides Operational Update Regarding Fractalkine Block Blockers KAN567 and KAND145	17/11
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/11
Kancera reports that the phase I study of KAND145 has received regulatory approval	23-10-23
Kancera AB Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145	23-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kancera AB

Aandelen

KAN

SE0015658570

Andere talen

Filters